Juniper Publishers-Cannabinoid Hyperemesis Syndrome; A Growing Concern for New Mexico
Juniper Publishers- Open Access Journal of Social Sciences & Management studies
Introduction
Marijuana is the most commonly used illicit drug in
the United States (22.2 million people have used it in the past month)
according to the 2015 National Survey on Drug Use and Health [1].
Marijuana use is more prevalent among males compared to females and more
likely to be used by adolescents and young adults. [2]. The overall
prevalence of marijuana use has remained stable in the United States at
4%, but the prevalence of cannabis related disorders has continued to
increase [3]. As of December 2016, more than half of all states in the
United States have a law legalizing marijuana for recreational or
medical use. [4]. In 2007, New Mexico became the 12th state to allow the
use of cannabis for medical use with the Lynn and Erin Compassionate
Use Act.
Cannabinoid Hyperemesis Syndrome (CHS) was first
described in 2004 by Allen and colleagues [5], and is characterized by
chronic cannabis use, cyclic episodes of nausea and vomiting, and the
learned behavior of hot bathing [5,6]. Several case reports have
described patients with chronic marijuana use presenting to healthcare
facilities with abdominal pain, cyclic vomiting, and compulsive
showering [7-15], but there are few epidemiologic studies that have
analyzed the association between marijuana use and CHS.
In this analysis, emergency department data from
2010-2015 was analyzed for CHS cases. The primary objective of this
study was to describe the prevalence of CHS over a 6-year period in New
Mexico. A secondary objective was to compare any CHS trends observed in
New Mexico to national estimates.
Materials and Methods
Study Sample and Variables
This study is a retrospective analysis of emergency
department (ED) data from hospitals across the state of New Mexico. This
data consists of ED visits from 36 non-federal hospitals. Data elements
included in this dataset include patient characteristics including age,
sex, and patient residence information as well as visit characteristics
including +/- 20 diagnosis fields, +/- 6 procedures codes (2015 only)
and visit and discharge information (dates and times).
Six years of New Mexico ED data were analyzed
(2010-2015) with an average of 765,000 visits per year. For this
analysis, the following ICD-9-CM and ICD-10-CM codes were used: Cannabis
Related Diagnosis Codes [ICD-9-CM: 304.3, 304.30, 304.31, 305.20,
305.21; ICD-10-CM: F12.10, F12.2, F12.20, F12.9, F12.90]
and Persistent Vomiting [ICD-9-CM: 536.2; ICD-10-CM: R11.10].
A CHS case was defined as an ED visit with a cannabis related
diagnosis code and a persistent vomiting diagnosis code.
National Study Sample
For national estimates of ED visits, five years of emergency
department data were analyzed (2010-2014) using the
Nationwide Emergency Department Sample (NEDS), Healthcare
Cost and Utilization Project (HCUP), Agency for Healthcare
Research and Quality. (Healthcare Cost and Utilization Project
(HCUP), 2017) The NEDS dataset contains ED data from 30 states
with approximately 30 million ED visits each year. The NEDS
dataset can be weighted to yield national estimates [16].
Results
The annual number of total ED visits increased by 24.2%
from 2010 to 2015 in New Mexico. During this six-year period,
the annual number of ED visits for cannabis increased by 172.8%
and 585.7% for CHS visits (Table 1). On the national level, total
estimated ED visits increased 6.9% from 2010 to 2014 (same
period in New Mexico saw a 23.6% increase). National estimates
for cannabis ED visits increased 71.9% and CHS increased 423.3%.
In New Mexico, a higher percentage of CHS visits were
among males, between the age of 18-29 years, who resided in
the Northeast region of the state. A higher percentage of visits for
cannabis were male, between the age of 30-64 years, who resided
in the Northeast region of the state. For every year of ED analysis,
all four age groups (0-17, 18-29, 30-64, and 65+ years) had an
increase in the number of visits for cannabis. On a national level, a
higher percentage of CHS visits were male and between the age of
30-64 years. Visits for cannabis followed a similar pattern.
The number of visits for cannabis have been steadily increasing
from 2010-2015, with a very large increase from 2014-2015
(Figure 1). A similar trend was observed for CHS visits. Visits for
vomiting decreased in 2012, but then increased from 2013-2015,
with a similar large increase from 2014-2015 as observed for both
cannabis and CHS visits. The number of patients admitted for
CHS increased with each year (Table 1). On average, each patient
visited 1.5 times for CHS. Evaluating CHS and cannabis only visits
together, patients visited roughly 2 times per year (the range was
0-5 additional visits).
Discussion
Key Findings
In this analysis, we found that the number of ED visits for
patients presenting with CHS symptoms has increased from 2010
to 2015. Both the number of patients per year and the number
of visits has increased, with an average of 1.5 annual visits per
patient. A higher percentage of patients presenting with CHS
symptoms were male and between the age of 18-29 years. New
Mexico CHS patients differ from national CHS patients as New
Mexico patients are younger in age.
The New Mexico Medical Cannabis program (MCP) has
grown substantially. In 2012, the number of active patients in
the MCP was 8,059 New Mexico residents. At the end of 2015,
the number of active, purchasing members grew to 41,419 New
Mexico residents (https://nmhealth.org/about/mcp/svcs/pdb/).
A lot of the growth in MCP members is due to increased efficiency
in processing MCP registrations, additional health conditions
added to the list of qualifying conditions, and increased supply of
cannabis due to the addition of more licensed producers.
In an analysis of ED visits from two large Colorado hospitals
from 2008-2011, Kim et. al [17], found that the prevalence of
cyclic vomiting ED visits doubled after marijuana liberalization in
the state. Of the patients admitted for cyclic vomiting, marijuana
use was more likely documented after medical cannabis use
legislation went into effect (October 19, 2009). Cyclic vomiting
and CHS are very similar syndromes with the main difference
being a history of cannabis use among CHS patients [18].
The increase in the number of visits for CHS is concerning as
this may just be the tip of the iceberg regarding ED visit numbers.
Studies have shown that there is a delay in the onset of vomiting
illness in chronic cannabis users. The delay could be 1-2 years
before a CHS patient experiences heavy nausea, vomiting, and
abdominal pain. Hot showering or bathing can bring temporary
relief to CHS patients, but only cessation of cannabis use will cure
the patient [18,19]. Those patients that return to chronic cannabis
use after a period of cessation have the potential for relapse. Not
all chronic users of cannabis will develop CHS [19].
Most likely the national estimate is an underestimate of the
number of visits for both cannabis and CHS. Of the 30 states that
participate in NEDS, Colorado and Washington are not included.
Both states have recreational marijuana laws that went into effect
in 2012. Of the 9 jurisdictions that have recreational marijuana
laws (Alaska, California, Colorado, Maine, Massachusetts, Nevada,
Oregon, Washington, and Washington D.C) only Colorado and
Washington had laws that were enacted prior to 2015. Of the
29 jurisdictions that have medical marijuana laws, only 16 are
included in the NEDS dataset and had laws enacted prior to 2015.
Key states are missing from the NEDS dataset that would be
influential in estimating the national prevalence of CHS.
In an analysis of ED visits from two large Colorado hospitals
from 2008-2011, Kim et. al [17], found that the prevalence of
cyclic vomiting ED visits doubled after marijuana liberalization in
the state. Of the patients admitted for cyclic vomiting, marijuana
use was more likely documented after medical cannabis use
legislation went into effect (October 19, 2009). Cyclic vomiting
and CHS are very similar syndromes with the main difference
being a history of cannabis use among CHS patients [18].
Limitations
There are a few limitations for this study. First, this is a
retrospective study of emergency department data. The data was
not collected for analyzing CHS prevalence. Second, CHS cases were
identified by ICD-9-CM codes alone, and there is not a specific ICD-
9-CM code that identifies CHS. Other studies have used medical
records and doctor’s notes to identify CHS patients; access to
these data sources was not available for this analysis. Third, other
factors, in addition to the legalization of medical marijuana, could
play a role in the observed increase in CHS over time. Fourth, a
greater awareness of CHS by physicians’ over time could explain
some of the observed increase in CHS. Lastly, the collection of
emergency department data started in 2010, therefore it is not
possible to analyze CHS prior to or directly after legalization of
medical cannabis in New Mexico.
Conclusion
Currently cannabis is only available to individuals with a
medical need in New Mexico, but Colorado permits New Mexico
residents to purchase cannabis in Colorado. Several states are
moving to recreational use of cannabis and more states could
adopt recreational use legislation. With the increasing availability
and potential relaxing of legal restrictions on cannabis, recognition
of CHS patients by healthcare staff is paramount to reducing
healthcare costs. Diagnosing CHS can be hard as persistent
vomiting with no clear cause necessitates multiple expensive and
invasive medical procedures. Education of healthcare personnel
will assist with identifying and treating CHS patients, which will
ultimately lower healthcare costs.
For More Articles in Annals of Social Sciences & Management studies
Please Click on: https://juniperpublishers.com/asm/index.php
For More Open Access Journals In Juniper Publishers Please Click on: https://juniperpublishers.com/index.php
Comments
Post a Comment